Role of Histone Deacetylase and Inhibitors in Cardiovascular Diseases

Abstract

Histone deacetylase(HDAC) is Zn²⁺-dependent histone deacetylases that regulate the key signalling pathways involved in gene transcription. 11 isoforms have been identified. Recent in vitro and in vivo studies have shown that HDACs are involved in the pathophysiology of cardiovascular diseases (CVDs) and play important roles in cell proliferation, differentiation and mitochondrial metabolism. In terms of physiological mechanisms, HDAC1–6 may play important roles in normal cardiac development and physiological function, while HDAC7 regulates angiogenesis. In pathological processes, class I HDACs function as pro-hypertrophic mediators, whereas class II HDACs act as anti-hypertrophic mediators. HDAC1–3, 6, 9, and 11 participate in lipid cell formation, oxidative stress and endothelial cell injury through multiple signalling pathways, contributing to the pathogenesis of atherosclerosis. In addition, HDACs also play a role in CVDs such as heart failure, myocardial fibrosis, pulmonary hypertension and diabetic cardiomyopathy. In view of this, we reviewed the regulatory pathways and molecular targets of HDACs in the pathogenesis of CVD. In addition, we summarise the current discovery of inhibitors targeting HDACs. HDAC inhibitors have shown promising therapeutic progress in animal experiments, but clinical trials to demonstrate their efficacy in humans are still lacking. A better understanding of the role of HDACs in CVD provides a new direction for the development of therapeutic interventions and holds significant research value.

Keywords

cardiovascular diseases / cell proliferation / histone deacetylase / mitochondrial metabolism

References

[1] W. Fischle, S. Emiliani, M. J. Hendzel, et al., “A New Family of Human Histone Deacetylases Related to Saccharomyces cerevisiae HDA1p,” Journal of Biological Chemistry 274 (1999): 11713–11720.

[2] A. J. M. de Ruijter, A. H. van Gennip, H. N. Caron, et al., “Histone Deacetylases (HDACs): Characterization of the Classical HDAC Family,” Biochemical Journal 370 (2003): 737–749.

[3] J. Yang, J. He, M. Ismail, et al., “HDAC Inhibition Induces Autophagy and Mitochondrial Biogenesis to Maintain Mitochondrial Homeostasis During Cardiac Ischemia/Reperfusion Injury,” Journal of Molecular and Cellular Cardiology 130 (2019): 36–48, https://doi.org/10.1016/j.yjmcc.2019.03.008.

[4] T. V. Huynh, L. Rethi, C. C. Chung, et al., “Class I HDAC Modulates Angiotensin II-Induced Fibroblast Migration and Mitochondrial Overactivity,” European Journal of Clinical Investigation 52 (2022): e13712, https://doi.org/10.1111/eci.13712.

[5] C. Magnussen, F. M. Ojeda, D. P. Leong, et al., “Global Effect of Modifiable Risk Factors on Cardiovascular Disease and Mortality,” New England Journal of Medicine 389 (2023): 1273–1285, https://doi.org/10.1056/NEJMoa2206916.

[6] P. Li, J. Ge, and H. Li, “Lysine Acetyltransferases and Lysine Deacetylases as Targets for Cardiovascular Disease,” Nature Reviews. Cardiology 17 (2020): 96–115, https://doi.org/10.1038/s41569-019-0235-9.

[7] L. Gao, M. A. Cueto, F. Asselbergs, et al., “Cloning and Functional Characterization of HDAC11, a Novel Member of the Human Histone Deacetylase Family,” Journal of Biological Chemistry 277 (2002): 25748–25755, https://doi.org/10.1074/jbc.M111871200.

[8] B. C. Harrison, K. Huynh, G. L. Lundgaard, et al., “Protein Kinase C-Related Kinase Targets Nuclear Localization Signals in a Subset of Class IIa Histone Deacetylases,” FEBS Letters 584 (2010): 1103–1110, https://doi.org/10.1016/j.febslet.2010.02.057.

[9] T. G. Nishino, M. Miyazaki, H. Hoshino, et al., “14-3-3 Regulates the Nuclear Import of Class IIa Histone Deacetylases,” Biochemical and Biophysical Research Communications 377 (2008): 852–856, https://doi.org/10.1016/j.bbrc.2008.10.079.

[10] C. C. Sucharov, S. Langer, M. Bristow, et al., “Shuttling of HDAC5 in H9C2 Cells Regulates YY1 Function Through CaMKIV/PKD and PP2A,” American Journal of Physiology. Cell Physiology 291 (2006): C1029–C1037.

[11] X. Zhao, A. Ito, C. D. Kane, et al., “The Modular Nature of Histone Deacetylase HDAC4 Confers Phosphorylation-Dependent Intracellular Trafficking,” Journal of Biological Chemistry 276 (2001): 35042–35048.

[12] E. A. Miska, E. Langley, D. Wolf, et al., “Differential Localization of HDAC4 Orchestrates Muscle Differentiation,” Nucleic Acids Research 29 (2001): 3439–3447.

[13] F. Yao, Z. Jin, Z. Zheng, et al., “HDAC11 Promotes Both NLRP3/Caspase-1/GSDMD and Caspase-3/GSDME Pathways Causing Pyroptosis via ERG in Vascular Endothelial Cells,” Cell Death Discovery 8 (2022): 112, https://doi.org/10.1038/s41420-022-00906-9.

[14] X. D. Fan, L. L. Wan, M. Duan, et al., “HDAC11 Deletion Reduces Fructose-Induced Cardiac Dyslipidemia, Apoptosis and Inflammation by Attenuating Oxidative Stress Injury,” Biochemical and Biophysical Research Communications 503 (2018): 444–451, https://doi.org/10.1016/j.bbrc.2018.04.090.

[15] Y. Li, X. Weng, P. Wang, et al., “4-Phenylbutyrate Exerts Stage-Specific Effects on Cardiac Differentiation via HDAC Inhibition,” PLoS One 16 (2021): e0250267, https://doi.org/10.1371/journal.pone.0250267.

[16] C. M. Trivedi, Y. Luo, Z. Yin, et al., “Hdac2 Regulates the Cardiac Hypertrophic Response by Modulating Gsk3 Beta Activity,” Nature Medicine 13 (2007): 324–331, https://doi.org/10.1038/nm1552.

[17] J. Jang, G. Song, S. M. Pettit, et al., “Epicardial HDAC3 Promotes Myocardial Growth Through a Novel MicroRNA Pathway,” Circulation Research 131 (2022): 151–164, https://doi.org/10.1161/CIRCRESAHA.122.320785.

[18] S. Karppinen, S. L. Hanninen, R. Rapila, and P. Tavi, “Sarcoplasmic Reticulum ca(2+) -Induced ca(2+) Release Regulates Class IIa HDAC Localization in Mouse Embryonic Cardiomyocytes,” Physiological Reports 6 (2018): e13522, https://doi.org/10.14814/phy2.13522.

[19] R. Ginnan, L. Y. Sun, J. J. Schwarz, et al., “MEF2 Is Regulated by CaMKIIdelta2 and a HDAC4-HDAC5 Heterodimer in Vascular Smooth Muscle Cells,” Biochemical Journal 444 (2012): 105–114, https://doi.org/10.1042/BJ20120152.

[20] Y. Kang, J. Kim, J. P. Anderson, et al., “Apelin-APJ Signaling Is a Critical Regulator of Endothelial MEF2 Activation in Cardiovascular Development,” Circulation Research 113 (2013): 22–31, https://doi.org/10.1161/CIRCRESAHA.113.301324.

[21] J. Ye, M. Llorian, M. Cardona, et al., “A Pathway Involving HDAC5, cFLIP and Caspases Regulates Expression of the Splicing Regulator Polypyrimidine Tract Binding Protein in the Heart,” Journal of Cell Science 126 (2013): 1682–1691, https://doi.org/10.1242/jcs.121384.

[22] Y.-S. Kim, M.-J. Kim, T.-H. Koo, et al., “Histone Deacetylase Is Required for the Activation of Wnt/β-Catenin Signaling Crucial for Heart Valve Formation in Zebrafish Embryos,” Biochemical and Biophysical Research Communications 423 (2012): 140–146, https://doi.org/10.1016/j.bbrc.2012.05.098.

[23] S. A. Samant, V. B. Pillai, N. R. Sundaresan, et al., “Histone Deacetylase 3 (HDAC3)-Dependent Reversible Lysine Acetylation of Cardiac Myosin Heavy Chain Isoforms Modulates Their Enzymatic and Motor Activity,” Journal of Biological Chemistry 290 (2015): 15559–15569, https://doi.org/10.1074/jbc.M115.653048.

[24] M. P. Gupta, S. A. Samant, S. H. Smith, et al., “HDAC4 and PCAF Bind to Cardiac Sarcomeres and Play a Role in Regulating Myofilament Contractile Activity,” Journal of Biological Chemistry 283 (2008): 10135–10146, https://doi.org/10.1074/jbc.M710277200.

[25] L. X. Zhang, J. Du, Y. T. Zhao, et al., “Transgenic Overexpression of Active HDAC4 in the Heart Attenuates Cardiac Function and Exacerbates Remodeling in Infarcted Myocardium,” Journal of Applied Physiology 125, no. 12 (2018): 1968–1978, https://doi.org/10.1152/japplphysiol.00006.2018.

[26] Y.-H. Lin, J. L. Major, T. Liebner, et al., “HDAC6 Modulates Myofibril Stiffness and Diastolic Function of the Heart,” Journal of Clinical Investigation 132 (2022): e148333, https://doi.org/10.1172/JCI148333.

[27] A. Margariti, A. Zampetaki, Q. Xiao, et al., “Histone Deacetylase 7 Controls Endothelial Cell Growth Through Modulation of Beta-Catenin,” Circulation Research 106 (2010): 1202–1211, https://doi.org/10.1161/CIRCRESAHA.109.213165.

[28] B. Zhou, A. Margariti, L. Zeng, et al., “Splicing of Histone Deacetylase 7 Modulates Smooth Muscle Cell Proliferation and Neointima Formation Through Nuclear β-Catenin Translocation,” Arteriosclerosis, Thrombosis, and Vascular Biology 31 (2011): 2676–2684, https://doi.org/10.1161/ATVBAHA.111.230888.

[29] Y. Wang, J. E. B. Curson, D. Ramnath, et al., “Histone Deacetylase 7 Activates 6-Phosphogluconate Dehydrogenase via an Enzyme-Independent Mechanism That Involves the N-Terminal Protein-Protein Interaction Domain,” Biochemical Journal 481 (2024): 1569–1584, https://doi.org/10.1042/BCJ20240380.

[30] C. L. Zhang, T. A. McKinsey, S. Chang, et al., “Class II Histone Deacetylases Act as Signal-Responsive Repressors of Cardiac Hypertrophy,” Cell 110 (2002): 479–488.

[31] S. Chang, T. A. McKinsey, C. L. Zhang, J. A. Richardson, J. A. Hill, and E. N. Olson, “Histone Deacetylases 5 and 9 Govern Responsiveness of the Heart to a Subset of Stress Signals and Play Redundant Roles in Heart Development,” Molecular and Cellular Biology 24 (2004): 8467–8476.

[32] J. Y. Ooi, N. K. Tuano, H. Rafehi, et al., “HDAC Inhibition Attenuates Cardiac Hypertrophy by Acetylation and Deacetylation of Target Genes,” Epigenetics 10 (2015): 418–430, https://doi.org/10.1080/15592294.2015.1024406.

[33] H. J. Kee and H. Kook, “Kruppel-Like Factor 4 Mediates Histone Deacetylase Inhibitor-Induced Prevention of Cardiac Hypertrophy,” Journal of Molecular and Cellular Cardiology 47 (2009): 770–780, https://doi.org/10.1016/j.yjmcc.2009.08.022.

[34] H. Yan, S. Yi, H. Zhuang, L. Wu, D. W. Wang, and J. Jiang, “Sphingosine-1-Phosphate Ameliorates the Cardiac Hypertrophic Response Through Inhibiting the Activity of Histone Deacetylase-2,” International Journal of Molecular Medicine 41 (2018): 1704–1714, https://doi.org/10.3892/ijmm.2017.3325.

[35] W. Liu, J. Liu, G. Wang, et al., “Down-Regulation of Histone Deacetylase 2 Attenuates Ventricular Arrhythmias in a Mouse Model of Cardiac Hypertrophy Through Up-Regulation of Kv Channel-Interacting Protein 2 Expression,” Cardiovascular Research 121 (2025): 424–439, https://doi.org/10.1093/cvr/cvaf008.

[36] S. Yoon, T. Kook, H.-K. Min, et al., “PP2A Negatively Regulates the Hypertrophic Response by Dephosphorylating HDAC2 S394 in the Heart,” Experimental & Molecular Medicine 50 (2018): 1–14, https://doi.org/10.1038/s12276-018-0121-2.

[37] G. H. Eom, Y. K. Cho, J.-H. Ko, et al., “Casein Kinase-2α1 Induces Hypertrophic Response by Phosphorylation of Histone Deacetylase 2 S394 and Its Activation in the Heart,” Circulation 123 (2011): 2392–2403, https://doi.org/10.1161/CIRCULATIONAHA.110.003665.

[38] G. H. Eom, Y. S. Nam, J. G. Oh, et al., “Regulation of Acetylation of Histone Deacetylase 2 by p300/CBP-Associated Factor/Histone Deacetylase 5 in the Development of Cardiac Hypertrophy,” Circulation Research 114 (2014): 1133–1143, https://doi.org/10.1161/CIRCRESAHA.114.303429.

[39] S. Yoon, M. Kim, H. K. Min, et al., “Inhibition of Heat Shock Protein 70 Blocks the Development of Cardiac Hypertrophy by Modulating the Phosphorylation of Histone Deacetylase 2,” Cardiovascular Research 115 (2019): 1850–1860, https://doi.org/10.1093/cvr/cvy317.

[40] H. J. Kee, G. H. Eom, H. Joung, et al., “Activation of Histone Deacetylase 2 by Inducible Heat Shock Protein 70 in Cardiac Hypertrophy,” Circulation Research 103 (2008): 1259–1269, https://doi.org/10.1161/01.RES.0000338570.27156.84.

[41] C. R. Morales, D. L. Li, Z. Pedrozo, et al., “Inhibition of Class I Histone Deacetylases Blunts Cardiac Hypertrophy Through TSC2-Dependent mTOR Repression,” Science Signaling 9 (2016): ra34, https://doi.org/10.1126/scisignal.aad5736.

[42] B. S. Ferguson, B. C. Harrison, M. Y. Jeong, et al., “Signal-Dependent Repression of DUSP5 by Class I HDACs Controls Nuclear ERK Activity and Cardiomyocyte Hypertrophy,” Proceedings of the National Academy of Sciences of the United States of America 110 (2013): 9806–9811, https://doi.org/10.1073/pnas.1301509110.

[43] T. Zhao, H. J. Kee, L. Bai, et al., “Selective HDAC8 Inhibition Attenuates Isoproterenol-Induced Cardiac Hypertrophy and Fibrosis via p38 MAPK Pathway,” Frontiers in Pharmacology 12 (2021): 677757, https://doi.org/10.3389/fphar.2021.677757.

[44] M. Yan, C. Chen, W. Gong, et al., “miR-21-3p Regulates Cardiac Hypertrophic Response by Targeting Histone Deacetylase-8,” Cardiovascular Research 105 (2015): 340–352, https://doi.org/10.1093/cvr/cvu254.

[45] N. Blasco, Y. Camara, E. Nunez, et al., “Cardiomyocyte Hypertrophy Induced by Endonuclease G Deficiency Requires Reactive Oxygen Radicals Accumulation and Is Inhibitable by the Micropeptide Humanin,” Redox Biology 16 (2018): 146–156, https://doi.org/10.1016/j.redox.2018.02.021.

[46] L. Zheng, J. Wang, R. Zhang, et al., “Angiotensin II Mediates Cardiomyocyte Hypertrophy in Atrial Cardiomyopathy via Epigenetic Transcriptional Regulation,” Computational and Mathematical Methods in Medicine 2022 (2022): 6312100, https://doi.org/10.1155/2022/6312100.

[47] A. Pedram, M. Razandi, R. Narayanan, et al., “Estrogen Regulates Histone Deacetylases to Prevent Cardiac Hypertrophy,” Molecular Biology of the Cell 24 (2013): 3805–3818, https://doi.org/10.1091/mbc.E13-08-0444.

[48] X. Zhang, Q. Wang, Z. Wang, et al., “Interaction Between A-Kinase Anchoring Protein 5 and Protein Kinase A Mediates CaMKII/HDAC Signaling to Inhibit Cardiomyocyte Hypertrophy After Hypoxic Reoxygenation,” Cellular Signalling 103 (2023): 110569, https://doi.org/10.1016/j.cellsig.2022.110569.

[49] K. L. Weeks, A. Ranieri, A. Karas, et al., “Beta-Adrenergic Stimulation Induces Histone Deacetylase 5 (HDAC5) Nuclear Accumulation in Cardiomyocytes by B55alpha-PP2A-Mediated Dephosphorylation,” Journal of the American Heart Association 6 (2017): e004861, https://doi.org/10.1161/JAHA.116.004861.

[50] W. Herrington, B. Lacey, P. Sherliker, et al., “Epidemiology of Atherosclerosis and the Potential to Reduce the Global Burden of Atherothrombotic Disease,” Circulation Research 118 (2016): 535–546, https://doi.org/10.1161/CIRCRESAHA.115.307611.

[51] L. Zhang, C. Xia, Y. Yang, et al., “DNA Methylation and Histone Post-Translational Modifications in Atherosclerosis and a Novel Perspective for Epigenetic Therapy,” Cell Communication and Signaling: CCS 21 (2023): 344, https://doi.org/10.1186/s12964-023-01298-8.

[52] W. Jiang, D. K. Agrawal, and C. S. Boosani, “Cell-Specific Histone Modifications in Atherosclerosis (Review),” Molecular Medicine Reports 18 (2018): 1215–1224, https://doi.org/10.3892/mmr.2018.9142.

[53] C. Hu, K. Peng, Q. Wu, et al., “HDAC1 and 2 Regulate Endothelial VCAM-1 Expression and Atherogenesis by Suppressing Methylation of the GATA6 Promoter,” Theranostics 11 (2021): 5605–5619, https://doi.org/10.7150/thno.55878.

[54] K. Bedenbender, I. Beinborn, E. Vollmeister, et al., “p38 and Casein Kinase 2 Mediate Ribonuclease 1 Repression in Inflamed Human Endothelial Cells via Promoter Remodeling Through Nucleosome Remodeling and Deacetylase Complex,” Frontiers in Cell and Development Biology 8 (2020): 563604, https://doi.org/10.3389/fcell.2020.563604.

[55] Y. Zhu, T. Wang, Y. Yang, et al., “Low Shear Stress Exacerbates Atherosclerosis by Inducing the Generation of Neutrophil Extracellular Traps via Piezo1-Mediated Mechanosensation,” Atherosclerosis 391 (2024): 117473, https://doi.org/10.1016/j.atherosclerosis.2024.117473.

[56] Y. Xu, P. K. Sengupta, E. Seto, et al., “Regulatory Factor for X-Box Family Proteins Differentially Interact With Histone Deacetylases to Repress Collagen alpha2(I) Gene (COL1A2) Expression,” Journal of Biological Chemistry 281 (2006): 9260–9270.

[57] X. Weng, X. Cheng, X. Wu, et al., “Sin3B Mediates Collagen Type I Gene Repression by Interferon Gamma in Vascular Smooth Muscle Cells,” Biochemical and Biophysical Research Communications 447 (2014): 263–270, https://doi.org/10.1016/j.bbrc.2014.03.140.

[58] D. Hori, Y. Nomura, M. Nakano, et al., “Endothelial-Specific Overexpression of Histone Deacetylase 2 Protects Mice Against Endothelial Dysfunction and Atherosclerosis,” Cellular Physiology and Biochemistry 54 (2020): 947–958, https://doi.org/10.33594/000000280.

[59] D. Pandey, G. Sikka, Y. Bergman, et al., “Transcriptional Regulation of Endothelial Arginase 2 by Histone Deacetylase 2,” Arteriosclerosis, Thrombosis, and Vascular Biology 34 (2014): 1556–1566, https://doi.org/10.1161/ATVBAHA.114.303685.

[60] Y. Xiong, G. Yepuri, M. Forbiteh, et al., “ARG2 Impairs Endothelial Autophagy Through Regulation of MTOR and PRKAA/AMPK Signaling in Advanced Atherosclerosis,” Autophagy 10 (2014): 2223–2238, https://doi.org/10.4161/15548627.2014.981789.

[61] Y. Li, K. Zhang, and W. Mao, “Inhibition of miR-34a Prevents Endothelial Cell Apoptosis by Directly Targeting HDAC1 in the Setting of Atherosclerosis,” Molecular Medicine Reports 17 (2018): 4645–4650, https://doi.org/10.3892/mmr.2018.8411.

[62] H. Wang, K. Sugimoto, H. Lu, et al., “HDAC1-Mediated Deacetylation of HIF1alpha Prevents Atherosclerosis Progression by Promoting miR-224-3p-Mediated Inhibition of FOSL2,” Molecular Therapy-Nucleic Acids 23 (2021): 577–591, https://doi.org/10.1016/j.omtn.2020.10.044.

[63] H. Liu, H. Wang, J. Ma, et al., “MicroRNA-146a-3p/HDAC1/KLF5/IKBα Signal Axis Modulates Plaque Formation of Atherosclerosis Mice,” Life Sciences 284 (2021): 119615, https://doi.org/10.1016/j.lfs.2021.119615.

[64] S. Zhou, P. Liu, G. Zhang, et al., “Histone Deacetylase 1 Depletion Alleviates Coronary Heart Disease via the MicroRNA-182-Mediated Transforming Growth Factor β/Smad Signaling Pathway,” Journal of Cardiovascular Pharmacology 79 (2022): 815–826, https://doi.org/10.1097/FJC.0000000000001260.

[65] A. Zampetaki, L. Zeng, A. Margariti, et al., “Histone Deacetylase 3 Is Critical in Endothelial Survival and Atherosclerosis Development in Response to Disturbed Flow,” Circulation 121 (2010): 132–142, https://doi.org/10.1161/CIRCULATIONAHA.109.890491.

[66] L. Chen, C. Shang, B. Wang, et al., “HDAC3 Inhibitor Suppresses Endothelial-To-Mesenchymal Transition via Modulating Inflammatory Response in Atherosclerosis,” Biochemical Pharmacology 192 (2021): 114716, https://doi.org/10.1016/j.bcp.2021.114716.

[67] X. H. Yu, W. Y. Deng, J. J. Chen, et al., “LncRNA kcnq1ot1 Promotes Lipid Accumulation and Accelerates Atherosclerosis via Functioning as a ceRNA Through the miR-452-3p/HDAC3/ABCA1 Axis,” Cell Death & Disease 11 (2020): 1043, https://doi.org/10.1038/s41419-020-03263-6.

[68] J. Van den Bossche, A. E. Neele, M. A. Hoeksema, et al., “Inhibiting Epigenetic Enzymes to Improve Atherogenic Macrophage Functions,” Biochemical and Biophysical Research Communications 455 (2014): 396–402, https://doi.org/10.1016/j.bbrc.2014.11.029.

[69] J. Wang, X. Xu, P. Li, et al., “HDAC3 Protects Against Atherosclerosis Through Inhibition of Inflammation via the microRNA-19b/PPARγ/NF-κB Axis,” Atherosclerosis 323 (2021): 1–12, https://doi.org/10.1016/j.atherosclerosis.2021.02.013.

[70] X. Zhong, X. Wei, Y. Xu, et al., “The Lysine Methyltransferase SMYD2 Facilitates Neointimal Hyperplasia by Regulating the HDAC3-SRF Axis,” Acta Pharmaceutica Sinica B 14 (2024): 712–728, https://doi.org/10.1016/j.apsb.2023.11.012.

[71] Y. Asare, T. A. Campbell-James, Y. Bokov, et al., “Histone Deacetylase 9 Activates IKK to Regulate Atherosclerotic Plaque Vulnerability,” Circulation Research 127 (2020): 811–823, https://doi.org/10.1161/CIRCRESAHA.120.316743.

[72] L. Lecce, Y. Xu, B. V'Gangula, et al., “Histone Deacetylase 9 Promotes Endothelial-Mesenchymal Transition and an Unfavorable Atherosclerotic Plaque Phenotype,” Journal of Clinical Investigation 131 (2021): e131178, https://doi.org/10.1172/JCI131178.

[73] X. Kuang, S. Chen, J. Lao, et al., “HDAC9 in the Injury of Vascular Endothelial Cell Mediated by P38 MAPK Pathway,” Journal of Interferon & Cytokine Research 41 (2021): 439–449, https://doi.org/10.1089/jir.2021.0050.

[74] X. Han, X. Han, Z. Wang, et al., “HDAC9 Regulates Ox-LDL-Induced Endothelial Cell Apoptosis by Participating in Inflammatory Reactions,” Frontiers in Bioscience 21 (2016): 907–917.

[75] R. Zhang and J. Ge, “Proteinase-Activated Receptor-2 Modulates Ve-Cadherin Expression to Affect Human Vascular Endothelial Barrier Function,” Journal of Cellular Biochemistry 118 (2017): 4587–4593, https://doi.org/10.1002/jcb.26123.

[76] T. M. Leucker, Y. Nomura, J. H. Kim, et al., “Cystathionine γ-Lyase Protects Vascular Endothelium: A Role for Inhibition of Histone Deacetylase 6,” American Journal of Physiology. Heart and Circulatory Physiology 312 (2017): H711–H720, https://doi.org/10.1152/ajpheart.00724.2016.

[77] M. Arrigo, M. Jessup, W. Mullens, et al., “Acute Heart Failure,” Nature Reviews. Disease Primers 6 (2020): 16, https://doi.org/10.1038/s41572-020-0151-7.

[78] E. M. Boorsma, J. M. Ter Maaten, K. Damman, et al., “Congestion in Heart Failure: A Contemporary Look at Physiology, Diagnosis and Treatment,” Nature Reviews. Cardiology 17 (2020): 641–655, https://doi.org/10.1038/s41569-020-0379-7.

[79] S. G. K. Yoo, C. S. P. Lam, and N. K. Sweitzer, “Asian Heart Failure,” Circulation 150 (2024): 177–179, https://doi.org/10.1161/CIRCULATIONAHA.123.068576.

[80] P. P. Liao, L. H. Liu, B. Wang, et al., “Correlation Between Histone Deacetylase 9 and Regulatory T Cell in Patients With Chronic Heart Failure,” Current Medical Science 38 (2018): 199–203, https://doi.org/10.1007/s11596-018-1866-5.

[81] Y.-Y. Wang, B. Gao, Y. Yang, et al., “Histone Deacetylase 3 Suppresses the Expression of SHP-1 via Deacetylation of DNMT1 to Promote Heart Failure,” Life Sciences 292 (2022): 119552, https://doi.org/10.1016/j.lfs.2021.119552.

[82] L. H. Lehmann, Z. H. Jebessa, M. M. Kreusser, et al., “A Proteolytic Fragment of Histone Deacetylase 4 Protects the Heart From Failure by Regulating the Hexosamine Biosynthetic Pathway,” Nature Medicine 24 (2018): 62–72, https://doi.org/10.1038/nm.4452.

[83] F. Yang, Z. Zhao, D. Zhang, et al., “Single-Cell Multi-Omics Analysis of Lineage Development and Spatial Organization in the Human Fetal Cerebellum,” Cell Discovery 10 (2024): 22, https://doi.org/10.1038/s41421-024-00656-1.

[84] N. Dörmann, E. Hammer, K. Struckmann, et al., “Metabolic Remodeling in Cardiac Hypertrophy and Heart Failure With Reduced Ejection Fraction Occurs Independent of Transcription Factor EB in Mice,” Frontiers in Cardiovascular Medicine 10 (2023): 1323760, https://doi.org/10.3389/fcvm.2023.1323760.

[85] B. Lkhagva, Y.-H. Kao, T.-I. Lee, et al., “Activation of Class I Histone Deacetylases Contributes to Mitochondrial Dysfunction in Cardiomyocytes With Altered Complex Activities,” Epigenetics 13 (2018): 376–385, https://doi.org/10.1080/15592294.2018.1460032.

[86] H. F. Nural-Guvener, L. Zakharova, J. Nimlos, et al., “HDAC Class I Inhibitor, Mocetinostat, Reverses Cardiac Fibrosis in Heart Failure and Diminishes CD90+ Cardiac Myofibroblast Activation,” Fibrogenesis & Tissue Repair 7 (2014): 10, https://doi.org/10.1186/1755-1536-7-10.

[87] B. Lopez, S. Ravassa, M. U. Moreno, et al., “Diffuse Myocardial Fibrosis: Mechanisms, Diagnosis and Therapeutic Approaches,” Nature Reviews. Cardiology 18 (2021): 479–498, https://doi.org/10.1038/s41569-020-00504-1.

[88] A. Gonzalez, E. B. Schelbert, J. Diez, et al., “Myocardial Interstitial Fibrosis in Heart Failure: Biological and Translational Perspectives,” Journal of the American College of Cardiology 71 (2018): 1696–1706, https://doi.org/10.1016/j.jacc.2018.02.021.

[89] X. Li, Y. Yang, S. Chen, et al., “Epigenetics-Based Therapeutics for Myocardial Fibrosis,” Life Sciences 271 (2021): 119186, https://doi.org/10.1016/j.lfs.2021.119186.

[90] S. M. Williams, L. Golden-Mason, B. S. Ferguson, et al., “Class I HDACs Regulate Angiotensin II-Dependent Cardiac Fibrosis via Fibroblasts and Circulating Fibrocytes,” Journal of Molecular and Cellular Cardiology 67 (2014): 112–125, https://doi.org/10.1016/j.yjmcc.2013.12.013.

[91] N. K. Somanna, A. J. Valente, M. Krenz, et al., “Histone Deacetyltransferase Inhibitors Trichostatin A and Mocetinostat Differentially Regulate MMP9, IL-18 and RECK Expression, and Attenuate Angiotensin II-Induced Cardiac Fibroblast Migration and Proliferation,” Hypertension Research 39 (2016): 709–716, https://doi.org/10.1038/hr.2016.54.

[92] Y. Zhang, F. Gao, Y. Tang, et al., “Valproic Acid Regulates Ang II-Induced Pericyte-Myofibroblast Trans-Differentiation via MAPK/ERK Pathway,” American Journal of Translational Research 10 (2018): 1976–1989.

[93] H. Nural-Guvener, L. Zakharova, L. Feehery, et al., “Anti-Fibrotic Effects of Class I HDAC Inhibitor, Mocetinostat Is Associated With IL-6/Stat3 Signaling in Ischemic Heart Failure,” International Journal of Molecular Sciences 16 (2015): 11482–11499, https://doi.org/10.3390/ijms160511482.

[94] H. Tao, J. J. Yang, W. Hu, K.-H. Shi, and J. Li, “HDAC6 Promotes Cardiac Fibrosis Progression Through Suppressing RASSF1A Expression,” Cardiology 133 (2016): 18–26, https://doi.org/10.1159/000438781.

[95] J. Fang, S. Shu, H. Dong, et al., “Histone Deacetylase 6 Controls Cardiac Fibrosis and Remodelling Through the Modulation of TGF-β1/Smad2/3 Signalling in Post-Infarction Mice,” Journal of Cellular and Molecular Medicine 28 (2024): e70063, https://doi.org/10.1111/jcmm.70063.

[96] S. Frantz, M. J. Hundertmark, J. Schulz-Menger, et al., “Left Ventricular Remodelling Post-Myocardial Infarction: Pathophysiology, Imaging, and Novel Therapies,” European Heart Journal 43 (2022): 2549–2561, https://doi.org/10.1093/eurheartj/ehac223.

[97] X. Han, C. Peng, L. Huang, et al., “EGCG Prevents Pressure Overload-Induced Myocardial Remodeling by Downregulating Overexpression of HDAC5 in Mice,” International Journal of Molecular Medicine 49 (2022): 11, https://doi.org/10.3892/ijmm.2021.5066.

[98] H. Jung, E. Lee, I. Kim, et al., “Histone Deacetylase Inhibition Attenuates Aortic Remodeling in Rats Under Pressure Overload,” BioMed Research International 2020 (2020): 4705615, https://doi.org/10.1155/2020/4705615.

[99] G. J. Kim, H. Jung, E. Lee, et al., “Histone Deacetylase Inhibitor, Mocetinostat, Regulates Cardiac Remodelling and Renin-Angiotensin System Activity in Rats With Transverse Aortic Constriction-Induced Pressure Overload Cardiac Hypertrophy,” Reviews in Cardiovascular Medicine 22 (2021): 1037–1045, https://doi.org/10.31083/j.rcm2203113.

[100] G. R. Kim, S.-N. Cho, H.-S. Kim, et al., “Histone Deacetylase and GATA-Binding Factor 6 Regulate Arterial Remodeling in Angiotensin II-Induced Hypertension,” Journal of Hypertension 34 (2016): 2206–2219, https://doi.org/10.1097/HJH.0000000000001081.

[101] V. Truong, A. Jain, M. B. Anand-Srivastava, and A. K. Srivastava, “Angiotensin II-Induced Histone Deacetylase 5 Phosphorylation, Nuclear Export, and Egr-1 Expression Are Mediated by Akt Pathway in A10 Vascular Smooth Muscle Cells,” American Journal of Physiology. Heart and Circulatory Physiology 320 (2021): H1543–H1554, https://doi.org/10.1152/ajpheart.00683.2020.

[102] D. J. Hausenloy and D. M. Yellon, “Myocardial Ischemia-Reperfusion Injury: A Neglected Therapeutic Target,” Journal of Clinical Investigation 123 (2013): 92–100, https://doi.org/10.1172/JCI62874.

[103] Z. Wu, Y. Bai, Y. Qi, et al., “HDAC1 Disrupts the Tricarboxylic Acid (TCA) Cycle Through the Deacetylation of Nur77 and Promotes Inflammation in Ischemia-Reperfusion Mice,” Cell Death Discovery 9 (2023): 10, https://doi.org/10.1038/s41420-023-01308-1.

[104] D. J. Herr, M. Baarine, S. E. Aune, et al., “HDAC1 Localizes to the Mitochondria of Cardiac Myocytes and Contributes to Early Cardiac Reperfusion Injury,” Journal of Molecular and Cellular Cardiology 114 (2018): 309–319, https://doi.org/10.1016/j.yjmcc.2017.12.004.

[105] J. B. Moore, J. Zhao, M. C. L. Keith, et al., “The Epigenetic Regulator HDAC1 Modulates Transcription of a Core Cardiogenic Program in Human Cardiac Mesenchymal Stromal Cells Through a p53-Dependent Mechanism,” Stem Cells 34 (2016): 2916–2929, https://doi.org/10.1002/stem.2471.

[106] L. Zhang, H. Wang, Y. Zhao, et al., “Myocyte-Specific Overexpressing HDAC4 Promotes Myocardial Ischemia/Reperfusion Injury,” Molecular Medicine 24 (2018): 37, https://doi.org/10.1186/s10020-018-0037-2.

[107] E. K. Youn, H. M. Cho, J. K. Jung, et al., “Pathologic HDAC1/c-Myc Signaling Axis Is Responsible for Angiotensinogen Transcription and Hypertension Induced by High-Fat Diet,” Biomedicine & Pharmacotherapy 164 (2023): 114926, https://doi.org/10.1016/j.biopha.2023.114926.

[108] H. J. Kee, Y. Ryu, Y. M. Seok, et al., “Selective Inhibition of Histone Deacetylase 8 Improves Vascular Hypertrophy, Relaxation, and Inflammation in Angiotensin II Hypertensive Mice,” Clinical Hypertension 25 (2019): 13, https://doi.org/10.1186/s40885-019-0118-8.

[109] L. Bai, H. J. Kee, S. Y. Choi, et al., “HDAC5 Inhibition Reduces Angiotensin II-Induced Vascular Contraction, Hypertrophy, and Oxidative Stress in a Mouse Model,” Biomedicine & Pharmacotherapy 134 (2021): 111162, https://doi.org/10.1016/j.biopha.2020.111162.

[110] N. Wang, Y.-J. Peng, and X. Su, “Histone Deacetylase 5 Is an Early Epigenetic Regulator of Intermittent Hypoxia Induced Sympathetic Nerve Activation and Blood Pressure,” Frontiers in Physiology 12 (2021): 688322, https://doi.org/10.3389/fphys.2021.688322.

[111] Z. Chi, H.-E. Byeon, E. Seo, et al., “Histone Deacetylase 6 Inhibitor Tubastatin A Attenuates Angiotensin II-Induced Hypertension by Preventing Cystathionine γ-Lyase Protein Degradation,” Pharmacological Research 146 (2019): 104281, https://doi.org/10.1016/j.phrs.2019.104281.

[112] R. Savai, S. S. Pullamsetti, J. Kolbe, et al., “Immune and Inflammatory Cell Involvement in the Pathology of Idiopathic Pulmonary Arterial Hypertension,” American Journal of Respiratory and Critical Care Medicine 186 (2012): 897–908, https://doi.org/10.1164/rccm.201202-0335OC.

[113] M. Humbert, C. Guignabert, S. Bonnet, et al., “Pathology and Pathobiology of Pulmonary Hypertension: State of the Art and Research Perspectives,” European Respiratory Journal 53 (2019): 1801887, https://doi.org/10.1183/13993003.01887-2018.

[114] P. Chelladurai, S. Dabral, S. R. Basineni, et al., “Isoform-Specific Characterization of Class I Histone Deacetylases and Their Therapeutic Modulation in Pulmonary Hypertension,” Scientific Reports 10 (2020): 12864, https://doi.org/10.1038/s41598-020-69737-x.

[115] F. Li, D. Wang, H. Wang, L. Chen, X. Sun, and Y. Wan, “Inhibition of HDAC1 Alleviates Monocrotaline-Induced Pulmonary Arterial Remodeling Through Up-Regulation of miR-34a,” Respiratory Research 22 (2021): 239, https://doi.org/10.1186/s12931-021-01832-7.

[116] H. Zhang, D. Wang, M. Li, et al., “Metabolic and Proliferative State of Vascular Adventitial Fibroblasts in Pulmonary Hypertension Is Regulated Through a MicroRNA-124/PTBP1 (Polypyrimidine Tract Binding Protein 1)/pyruvate Kinase Muscle Axis,” Circulation 136 (2017): 2468–2485, https://doi.org/10.1161/CIRCULATIONAHA.117.028069.

[117] H. Zhang, A. Laux, K. R. Stenmark, et al., “Mechanisms Contributing to the Dysregulation of miRNA-124 in Pulmonary Hypertension,” International Journal of Molecular Sciences 22 (2021): 3852, https://doi.org/10.3390/ijms22083852.

[118] M. Galletti, S. Cantoni, F. Zambelli, et al., “Dissecting Histone Deacetylase Role in Pulmonary Arterial Smooth Muscle Cell Proliferation and Migration,” Biochemical Pharmacology 91 (2014): 181–190, https://doi.org/10.1016/j.bcp.2014.07.011.

[119] Q. Yang, M. Sun, R. Ramchandran, et al., “IGF-1 Signaling in Neonatal Hypoxia-Induced Pulmonary Hypertension: Role of Epigenetic Regulation,” Vascular Pharmacology 73 (2015): 20–31, https://doi.org/10.1016/j.vph.2015.04.005.

[120] F. Chen, X. Li, E. Aquadro, et al., “Inhibition of Histone Deacetylase Reduces Transcription of NADPH Oxidases and ROS Production and Ameliorates Pulmonary Arterial Hypertension,” Free Radical Biology & Medicine 99 (2016): 167–178, https://doi.org/10.1016/j.freeradbiomed.2016.08.003.

[121] E. Nozik-Grayck, C. Woods, R. S. Stearman, et al., “Histone Deacetylation Contributes to Low Extracellular Superoxide Dismutase Expression in Human Idiopathic Pulmonary Arterial Hypertension,” American Journal of Physiology. Lung Cellular and Molecular Physiology 311 (2016): L124–L134, https://doi.org/10.1152/ajplung.00263.2015.

[122] L. Plecitá-Hlavatá, A. Brázdová, M. Křivonosková, et al., “Microenvironmental Regulation of T-Cells in Pulmonary Hypertension,” Frontiers in Immunology 14 (2023): 1223122, https://doi.org/10.3389/fimmu.2023.1223122.

[123] C.-N. Chen, N. Hajji, F.-C. Yeh, et al., “Restoration of Foxp3+ Regulatory T Cells by HDAC-Dependent Epigenetic Modulation Plays a Pivotal Role in Resolving Pulmonary Arterial Hypertension Pathology,” American Journal of Respiratory and Critical Care Medicine 208 (2023): 879–895, https://doi.org/10.1164/rccm.202301-0181OC.

[124] J. Kim, C. Hwangbo, X. Hu, et al., “Restoration of Impaired Endothelial Myocyte Enhancer Factor 2 Function Rescues Pulmonary Arterial Hypertension,” Circulation 131 (2015): 190–199, https://doi.org/10.1161/CIRCULATIONAHA.114.013339.

[125] G. Jia, A. Whaley-Connell, and J. R. Sowers, “Diabetic Cardiomyopathy: A Hyperglycaemia- and Insulin-Resistance-Induced Heart Disease,” Diabetologia 61 (2018): 21–28, https://doi.org/10.1007/s00125-017-4390-4.

[126] K. S. Olaniyi, O. A. Amusa, E. D. Areola, et al., “Suppression of HDAC by Sodium Acetate Rectifies Cardiac Metabolic Disturbance in Streptozotocin-Nicotinamide-Induced Diabetic Rats,” Experimental Biology and Medicine 245 (2020): 667–676, https://doi.org/10.1177/1535370220913847.

[127] C. Ouyang, L. Huang, X. Ye, M. Ren, and Z. Han, “HDAC1 Promotes Myocardial Fibrosis in Diabetic Cardiomyopathy by Inhibiting BMP-7 Transcription Through Histone Deacetylation,” Experimental and Clinical Endocrinology & Diabetes 130 (2022): 660–670, https://doi.org/10.1055/a-1780-8768.

[128] Y. Du, Y. Duan, J. Zhao, et al., “Dysfunctional APPL1-Mediated Epigenetic Regulation in Diabetic Vascular Injury,” Arteriosclerosis, Thrombosis, and Vascular Biology 43 (2023): e491–e508, https://doi.org/10.1161/ATVBAHA.122.318752.

[129] Z. Xu, Q. Tong, Z. Zhang, et al., “Inhibition of HDAC3 Prevents Diabetic Cardiomyopathy in OVE26 Mice via Epigenetic Regulation of DUSP5-ERK1/2 Pathway,” Clinical Science 131 (2017): 1841–1857, https://doi.org/10.1042/CS20170064.

[130] S.-I. Oka, F. Tang, A. Chin, et al., “β-Hydroxybutyrate, a Ketone Body, Potentiates the Antioxidant Defense via Thioredoxin 1 Upregulation in Cardiomyocytes,” Antioxidants 10 (2021): 1153, https://doi.org/10.3390/antiox10071153.

[131] B. Li, Y. Yu, K. Liu, et al., “β-Hydroxybutyrate Inhibits Histone Deacetylase 3 to Promote Claudin-5 Generation and Attenuate Cardiac Microvascular Hyperpermeability in Diabetes,” Diabetologia 64 (2021): 226–239, https://doi.org/10.1007/s00125-020-05305-2.

[132] M. Kronlage, M. Dewenter, J. Grosso, et al., “O-GlcNAcylation of Histone Deacetylase 4 Protects the Diabetic Heart From Failure,” Circulation 140 (2019): 580–594, https://doi.org/10.1161/CIRCULATIONAHA.117.031942.

[133] G. Zou, W. Zhong, F. Wu, et al., “Catalpol Attenuates Cardiomyocyte Apoptosis in Diabetic Cardiomyopathy via Neat1/miR-140-5p/HDAC4 Axis,” Biochimie 165 (2019): 90–99, https://doi.org/10.1016/j.biochi.2019.05.005.

[134] P. Syren, A.-K. Rahm, P. A. Schweizer, et al., “Histone Deacetylase 2-Dependent Ventricular Electrical Remodeling in a Porcine Model of Early Heart Failure,” Life Sciences 281 (2021): 119769, https://doi.org/10.1016/j.lfs.2021.119769.

[135] A.-K. Rahm, T. Wieder, D. Gramlich, et al., “HDAC2-Dependent Remodeling of KCa2.2 (KCNN2) and KCa2.3 (KCNN3) K+ Channels in Atrial Fibrillation With Concomitant Heart Failure,” Life Sciences 266 (2021): 118892, https://doi.org/10.1016/j.lfs.2020.118892.

[136] A.-K. Rahm, T. Wieder, D. Gramlich, et al., “Differential Regulation of KCa 2.1 (KCNN1) K+ Channel Expression by Histone Deacetylases in Atrial Fibrillation With Concomitant Heart Failure,” Physiological Reports 9 (2021): e14835, https://doi.org/10.14814/phy2.14835.

[137] B. Lkhagva, S. L. Chang, Y. C. Chen, et al., “Histone Deacetylase Inhibition Reduces Pulmonary Vein Arrhythmogenesis Through Calcium Regulation,” International Journal of Cardiology 177 (2014): 982–989, https://doi.org/10.1016/j.ijcard.2014.09.175.

[138] M. Seki, R. LaCanna, J. C. Powers, et al., “Class I Histone Deacetylase Inhibition for the Treatment of Sustained Atrial Fibrillation,” Journal of Pharmacology and Experimental Therapeutics 358 (2016): 441–449, https://doi.org/10.1124/jpet.116.234591.

[139] R. Miksiunas, K. Rucinskas, V. Janusauskas, et al., “Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Improves Energetic Status and Cardiomyogenic Differentiation of Human Dilated Myocardium-Derived Primary Mesenchymal Cells,” International Journal of Molecular Sciences 21 (2020): 4845, https://doi.org/10.3390/ijms21144845.

[140] L. Zhou, X. He, B. Gao, et al., “Inhibition of Histone Deacetylase Activity Aggravates Coxsackievirus B3-Induced Myocarditis by Promoting Viral Replication and Myocardial Apoptosis,” Journal of Virology 89 (2015): 10512–10523, https://doi.org/10.1128/JVI.01028-15.

[141] Z. Dang, H. Li, S. Xue, et al., “Histone Deacetylase 9-Mediated Phenotypic Transformation of Vascular Smooth Muscle Cells Is a Potential Target for Treating Aortic Aneurysm/Dissection,” Biomedicine & Pharmacotherapy 173 (2024): 116396, https://doi.org/10.1016/j.biopha.2024.116396.

[142] H. Zhu, L. Shan, P. W. Schiller, et al., “Histone Deacetylase-3 Activation Promotes Tumor Necrosis Factor-Alpha (TNF-Alpha) Expression in Cardiomyocytes During Lipopolysaccharide Stimulation,” Journal of Biological Chemistry 285 (2010): 9429–9436, https://doi.org/10.1074/jbc.M109.071274.

[143] X. Shi, X. Lv, and D. Xiao, “Gossypol Improves Myocardial Dysfunction Caused by Sepsis by Regulating Histone Acetylation,” Clinical and Translational Science 16 (2023): 2189–2197, https://doi.org/10.1111/cts.13618.

[144] K. Wang, R. Tang, S. Wang, et al., “Isoform-Selective HDAC Inhibitor Mocetinostat (MGCD0103) Alleviates Myocardial Ischemia/Reperfusion Injury via Mitochondrial Protection Through the HDACs/CREB/PGC-1α Signaling Pathway,” Journal of Cardiovascular Pharmacology 79 (2022): 217–228, https://doi.org/10.1097/FJC.0000000000001174.

[145] D. M. Barbosa, P. Fahlbusch, D. Herzfeld de Wiza, et al., “Rhein, a Novel Histone Deacetylase (HDAC) Inhibitor With Antifibrotic Potency in Human Myocardial Fibrosis,” Scientific Reports 10 (2020): 4888, https://doi.org/10.1038/s41598-020-61886-3.

[146] S. Guerra-Ojeda, A. Suarez, B. Belmonte, et al., “Sodium Valproate Treatment Reverses Endothelial Dysfunction in Aorta From Rabbits With Acute Myocardial Infarction,” European Journal of Pharmacology 970 (2024): 176475, https://doi.org/10.1016/j.ejphar.2024.176475.

[147] B. Lan, E. Hayama, N. Kawaguchi, et al., “Therapeutic Efficacy of Valproic Acid in a Combined Monocrotaline and Chronic Hypoxia Rat Model of Severe Pulmonary Hypertension,” PLoS One 10 (2015): e0117211, https://doi.org/10.1371/journal.pone.0117211.

[148] J. Choi, S. Park, T. K. Kwon, et al., “Role of the Histone Deacetylase Inhibitor Valproic Acid in High-Fat Diet-Induced Hypertension via Inhibition of HDAC1/Angiotensin II Axis,” International Journal of Obesity 41 (2017): 1702–1709, https://doi.org/10.1038/ijo.2017.166.

[149] S.-H. Kang, Y. M. Seok, M.-j. Song, H. A. Lee, T. Kurz, and I. Kim, “Histone Deacetylase Inhibition Attenuates Cardiac Hypertrophy and Fibrosis Through Acetylation of Mineralocorticoid Receptor in Spontaneously Hypertensive Rats,” Molecular Pharmacology 87 (2015): 782–791, https://doi.org/10.1124/mol.114.096974.

[150] J. Lamothe, S. Khurana, S. Tharmalingam, et al., “The Role of DNMT and HDACs in the Fetal Programming of Hypertension by Glucocorticoids,” Oxidative Medicine and Cellular Longevity 2020 (2020): 5751768, https://doi.org/10.1155/2020/5751768.

[151] B. Scholz, J. S. Schulte, S. Hamer, et al., “HDAC (Histone Deacetylase) Inhibitor Valproic Acid Attenuates Atrial Remodeling and Delays the Onset of Atrial Fibrillation in Mice,” Circulation. Arrhythmia and Electrophysiology 12 (2019): e007071, https://doi.org/10.1161/CIRCEP.118.007071.

[152] S. Ranjbarvaziri, A. Zeng, I. Wu, et al., “Targeting HDAC6 to Treat Heart Failure With Preserved Ejection Fraction in Mice,” Nature Communications 15 (2024): 1352, https://doi.org/10.1038/s41467-024-45440-7.

[153] B. Lkhagva, Y. K. Lin, Y. H. Kao, et al., “Novel Histone Deacetylase Inhibitor Modulates Cardiac Peroxisome Proliferator-Activated Receptors and Inflammatory Cytokines in Heart Failure,” Pharmacology 96 (2015): 184–191, https://doi.org/10.1159/000438864.

[154] T. I. Lee, K. J. Bai, Y. C. Chen, et al., “Histone Deacetylase Inhibition of Cardiac Autophagy in Rats on a High-Fat Diet With Low-Dose Streptozotocin-Induced Type 2 Diabetes Mellitus,” Molecular Medicine Reports 17 (2018): 594–601, https://doi.org/10.3892/mmr.2017.7905.

[155] T. I. Lee, Y. H. Kao, W. C. Tsai, C.-C. Chung, Y.-C. Chen, and Y.-J. Chen, “HDAC Inhibition Modulates Cardiac PPARs and Fatty Acid Metabolism in Diabetic Cardiomyopathy,” PPAR Research 2016 (2016): 5938740, https://doi.org/10.1155/2016/5938740.

[156] Y. H. Kao, J. P. Liou, C. C. Chung, et al., “Histone Deacetylase Inhibition Improved Cardiac Functions With Direct Antifibrotic Activity in Heart Failure,” International Journal of Cardiology 168 (2013): 4178–4183, https://doi.org/10.1016/j.ijcard.2013.07.111.

[157] J. K. Freundt, G. Frommeyer, T. Spieker, et al., “Histone Deacetylase Inhibition by Entinostat for the Prevention of Electrical and Structural Remodeling in Heart Failure,” BMC Pharmacology and Toxicology 20 (2019): 16, https://doi.org/10.1186/s40360-019-0294-x.

[158] S. E. Aune, D. J. Herr, S. K. Mani, et al., “Selective Inhibition of Class I but Not Class IIb Histone Deacetylases Exerts Cardiac Protection From Ischemia Reperfusion,” Journal of Molecular and Cellular Cardiology 72 (2014): 138–145, https://doi.org/10.1016/j.yjmcc.2014.03.005.

[159] Y. Ryu, H. J. Kee, S. Sun, et al., “Class I Histone Deacetylase Inhibitor MS-275 Attenuates Vasoconstriction and Inflammation in Angiotensin II-Induced Hypertension,” PLoS One 14 (2019): e0213186, https://doi.org/10.1371/journal.pone.0213186.

[160] M. Y. Jeong, Y. H. Lin, S. A. Wennersten, et al., “Histone Deacetylase Activity Governs Diastolic Dysfunction Through a Nongenomic Mechanism,” Science Translational Medicine 10 (2018): eaao0144, https://doi.org/10.1126/scitranslmed.aao0144.

[161] Q. Gao, A. Wei, F. Chen, et al., “Enhancing PPARγ by HDAC Inhibition Reduces Foam Cell Formation and Atherosclerosis in ApoE Deficient Mice,” Pharmacological Research 160 (2020): 105059, https://doi.org/10.1016/j.phrs.2020.105059.

[162] H. Jiang, S. Zhang, T. Song, et al., “Trichostatin a Protects Dendritic Cells Against Oxygen-Glucose Deprivation via the SRSF3/PKM2/Glycolytic Pathway,” Frontiers in Pharmacology 9 (2018): 612, https://doi.org/10.3389/fphar.2018.00612.

[163] T. C. Zhao, J. Du, S. Zhuang, et al., “HDAC Inhibition Elicits Myocardial Protective Effect Through Modulation of MKK3/Akt-1,” PLoS One 8 (2013): e65474, https://doi.org/10.1371/journal.pone.0065474.

[164] H. Ma, L. Yang, Y. Liu, et al., “Butyrate Suppresses Atherosclerotic Inflammation by Regulating Macrophages and Polarization via GPR43/HDAC-miRNAs Axis in ApoE−/− Mice,” PLoS One 18 (2023): e0282685, https://doi.org/10.1371/journal.pone.0282685.

[165] Y. Chen, J. Du, Y. T. Zhao, et al., “Histone Deacetylase (HDAC) Inhibition Improves Myocardial Function and Prevents Cardiac Remodeling in Diabetic Mice,” Cardiovascular Diabetology 14 (2015): 99, https://doi.org/10.1186/s12933-015-0262-8.

[166] V. Karoor, D. Strassheim, T. Sullivan, et al., “The Short-Chain Fatty Acid Butyrate Attenuates Pulmonary Vascular Remodeling and Inflammation in Hypoxia-Induced Pulmonary Hypertension,” International Journal of Molecular Sciences 22 (2021): 9916, https://doi.org/10.3390/ijms22189916.

[167] T. Song, X. Guan, X. Wang, et al., “Dynamic Modulation of Gut Microbiota Improves Post-Myocardial Infarct Tissue Repair in Rats via Butyric Acid-Mediated Histone Deacetylase Inhibition,” FASEB Journal 35 (2021): e21385, https://doi.org/10.1096/fj.201903129RRR.

[168] S.-A. Manea, M.-L. Vlad, I. M. Fenyo, et al., “Pharmacological Inhibition of Histone Deacetylase Reduces NADPH Oxidase Expression, Oxidative Stress and the Progression of Atherosclerotic Lesions in Hypercholesterolemic Apolipoprotein E-Deficient Mice; Potential Implications for Human Atherosclerosis,” Redox Biology 28 (2020): 101338, https://doi.org/10.1016/j.redox.2019.101338.

[169] D. Kimbrough, S. H. Wang, L. H. Wright, et al., “HDAC Inhibition Helps Post-MI Healing by Modulating Macrophage Polarization,” Journal of Molecular and Cellular Cardiology 119 (2018): 51–63, https://doi.org/10.1016/j.yjmcc.2018.04.011.

[170] L. Bocchi, B. M. Motta, M. Savi, et al., “The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) Restores Cardiomyocyte Contractility in a Rat Model of Early Diabetes,” International Journal of Molecular Sciences 20 (2019): 1873, https://doi.org/10.3390/ijms20081873.

[171] R. Miksiunas, R. Aldonyte, and A. Vailionyte, “Cardiomyogenic Differentiation Potential of Human Dilated Myocardium-Derived Mesenchymal Stem/Stromal Cells: The Impact of HDAC Inhibitor SAHA and Biomimetic Matrices,” International Journal of Molecular Sciences 22 (2021): 12702, https://doi.org/10.3390/ijms222312702.

[172] E. Lee, H.-A. Lee, M. Kim, et al., “Upregulation of C/EBPβ and TSC2 by an HDAC Inhibitor CG200745 Protects Heart From DOCA-Induced Hypertrophy,” Clinical and Experimental Pharmacology and Physiology 46 (2019): 226–236, https://doi.org/10.1111/1440-1681.13022.

[173] E. Lee, M.-J. Song, H.-A. Lee, et al., “Histone Deacetylase Inhibitor, CG200745, Attenuates Cardiac Hypertrophy and Fibrosis in DOCA-Induced Hypertensive Rats,” Korean Journal of Physiology & Pharmacology 20 (2016): 477–485, https://doi.org/10.4196/kjpp.2016.20.5.477.

[174] G.-E. Yoon, J. K. Jung, Y.-H. Lee, et al., “Histone Deacetylase Inhibitor CG200745 Ameliorates High-Fat Diet-Induced Hypertension via Inhibition of Angiotensin II Production,” Naunyn-Schmiedeberg's Archives of Pharmacology 393 (2020): 491–500, https://doi.org/10.1007/s00210-019-01749-5.

[175] P.-P. Pang, H. Sun, P.-X. Yu, et al., “The Hydroxamic Acid Derivative YPX-C-05 Alleviates Hypertension and Vascular Dysfunction Through the PI3K/Akt/eNOS Pathway,” Vascular Pharmacology 154 (2024): 107251, https://doi.org/10.1016/j.vph.2023.107251.

[176] Z. Chi, T. P. H. Le, S. K. Lee, et al., “Honokiol Ameliorates Angiotensin II-Induced Hypertension and Endothelial Dysfunction by Inhibiting HDAC6-Mediated Cystathionine γ-Lyase Degradation,” Journal of Cellular and Molecular Medicine 24 (2020): 10663–10676, https://doi.org/10.1111/jcmm.15686.

[177] Q. Yang, M. J. Dahl, K. H. Albertine, et al., “Role of Histone Deacetylases in Regulation of Phenotype of Ovine Newborn Pulmonary Arterial Smooth Muscle Cells,” Cell Proliferation 46 (2013): 654–664, https://doi.org/10.1111/cpr.12076.

[178] S. Y. Choi, H. J. Kee, S. Sun, et al., “Histone Deacetylase Inhibitor LMK235 Attenuates Vascular Constriction and Aortic Remodelling in Hypertension,” Journal of Cellular and Molecular Medicine 23 (2019): 2801–2812, https://doi.org/10.1111/jcmm.14188.

[179] T.-H. Wu, H.-C. Kuo, I. C. Lin, et al., “Melatonin Prevents Neonatal Dexamethasone Induced Programmed Hypertension: Histone Deacetylase Inhibition,” Journal of Steroid Biochemistry and Molecular Biology 144 (2014): 253–259, https://doi.org/10.1016/j.jsbmb.2014.07.008.

[180] A. M. Williams, W. He, Y. Li, et al., “Histone Deacetylase Inhibition Attenuates Cardiomyocyte Hypoxia-Reoxygenation Injury,” Current Molecular Medicine 18 (2018): 711–718, https://doi.org/10.2174/1566524019666190208102729.

[181] M. Xie, Y. Kong, W. Tan, et al., “Histone Deacetylase Inhibition Blunts Ischemia/Reperfusion Injury by Inducing Cardiomyocyte Autophagy,” Circulation 129 (2014): 1139–1151, https://doi.org/10.1161/CIRCULATIONAHA.113.002416.

[182] L. H. Wright, D. J. Herr, S. S. Brown, et al., “Angiokine Wisp-1 Is Increased in Myocardial Infarction and Regulates Cardiac Endothelial Signaling,” JCI Insight 3 (2018): e95824, https://doi.org/10.1172/jci.insight.95824.

[183] H. A. Lee, D. Y. Lee, H. M. Cho, et al., “Histone Deacetylase Inhibition Attenuates Transcriptional Activity of Mineralocorticoid Receptor Through Its Acetylation and Prevents Development of Hypertension,” Circulation Research 112 (2013): 1004–1012, https://doi.org/10.1161/CIRCRESAHA.113.301071.

[184] X. Shi, Y. Liu, D. Zhang, et al., “Valproic Acid Attenuates Sepsis-Induced Myocardial Dysfunction in Rats by Accelerating Autophagy Through the PTEN/AKT/mTOR Pathway,” Life Sciences 232 (2019): 116613, https://doi.org/10.1016/j.lfs.2019.116613.

[185] I. Paquin, S. Raeppel, S. Leit, et al., “Design and Synthesis of 4-[(s-Triazin-2-Ylamino)methyl]-N-(2-Aminophenyl)-Benzamides and Their Analogues as a Novel Class of Histone Deacetylase Inhibitors,” Bioorganic & Medicinal Chemistry Letters 18 (2008): 1067–1071.

[186] M. J. Lai, H. L. Huang, S. L. Pan, et al., “Synthesis and Biological Evaluation of 1-Arylsulfonyl-5-(N-Hydroxyacrylamide)indoles as Potent Histone Deacetylase Inhibitors With Antitumor Activity in Vivo,” Journal of Medicinal Chemistry 55 (2012): 3777–3791, https://doi.org/10.1021/jm300197a.

[187] A. Saito, T. Yamashita, Y. Mariko, et al., “A Synthetic Inhibitor of Histone Deacetylase, MS-27-275, With Marked in Vivo Antitumor Activity Against Human Tumors,” Proceedings of the National Academy of Sciences of the United States of America 96 (1999): 4592–4597, https://doi.org/10.1073/pnas.96.8.4592.

[188] J. B. Moore, X.-L. Tang, J. Zhao, et al., “Epigenetically Modified Cardiac Mesenchymal Stromal Cells Limit Myocardial Fibrosis and Promote Functional Recovery in a Model of Chronic Ischemic Cardiomyopathy,” Basic Research in Cardiology 114 (2018): 3, https://doi.org/10.1007/s00395-018-0710-1.

[189] B. M. Patel, “Sodium Butyrate Controls Cardiac Hypertrophy in Experimental Models of Rats,” Cardiovascular Toxicology 18 (2018): 1–8, https://doi.org/10.1007/s12012-017-9406-2.

[190] Z. Zhao, J. Lv, N. Guo, et al., “Dose-Dependent Effects of PRC2 and HDAC Inhibitors on Cardiomyocyte Hypertrophy Induced by Phenylephrine,” Current Drug Targets 24 (2023): 371–378, https://doi.org/10.2174/1389450124666230124094936.

[191] K. M. VanderMolen, W. McCulloch, C. J. Pearce, et al., “Romidepsin (Istodax, NSC 630176, FR901228, FK228, Depsipeptide): A Natural Product Recently Approved for Cutaneous T-Cell Lymphoma,” Journal of Antibiotics 64 (2011): 525–531, https://doi.org/10.1038/ja.2011.35.

[192] S. J. Haggarty, K. M. Koeller, J. C. Wong, et al., “Domain-Selective Small-Molecule Inhibitor of Histone Deacetylase 6 (HDAC6)-Mediated Tubulin Deacetylation,” Proceedings of the National Academy of Sciences of the United States of America 100 (2003): 4389–4394, https://doi.org/10.1073/pnas.0430973100.

[193] Y. N. Lamb, “Givinostat: First Approval,” Drugs 84 (2024): 849–856, https://doi.org/10.1007/s40265-024-02052-1.

[194] J. G. Travers, S. A. Wennersten, B. Peña, et al., “HDAC Inhibition Reverses Preexisting Diastolic Dysfunction and Blocks Covert Extracellular Matrix Remodeling,” Circulation 143 (2021): 1874–1890, https://doi.org/10.1161/CIRCULATIONAHA.120.046462.

[195] L. W. Evans, A. Bender, L. Burnett, et al., “Emodin and Emodin-Rich Rhubarb Inhibits Histone Deacetylase (HDAC) Activity and Cardiac Myocyte Hypertrophy,” Journal of Nutritional Biochemistry 79 (2020): 108339, https://doi.org/10.1016/j.jnutbio.2019.108339.

[196] L. Evans, T. Price, N. Hubert, et al., “Emodin Inhibited Pathological Cardiac Hypertrophy in Response to Angiotensin-Induced Hypertension and Altered the Gut Microbiome,” Biomolecules 13 (2023): 1274, https://doi.org/10.3390/biom13091274.

[197] F. Giles, T. Fischer, J. Cortes, et al., “A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients With Refractory Hematologic Malignancies,” Clinical Cancer Research 12 (2006): 4628–4635.

[198] M. H. Shah, P. Binkley, K. Chan, et al., “Cardiotoxicity of Histone Deacetylase Inhibitor Depsipeptide in Patients With Metastatic Neuroendocrine Tumors,” Clinical Cancer Research 12 (2006): 3997–4003.

[199] Q. Xu, D. Patel, X. Zhang, et al., “Changes in Cardiac Nav1.5 Expression, Function, and Acetylation by Pan-Histone Deacetylase Inhibitors,” American Journal of Physiology. Heart and Circulatory Physiology 311 (2016): H1139–H1149, https://doi.org/10.1152/ajpheart.00156.2016.

[200] M. Locatelli, C. Criscitiello, A. Esposito, et al., “QTc Prolongation Induced by Targeted Biotherapies Used in Clinical Practice and Under Investigation: A Comprehensive Review,” Targeted Oncology 10 (2015): 27–43, https://doi.org/10.1007/s11523-014-0325-x.

[201] S. Spence, M. Deurinck, H. Ju, et al., “Histone Deacetylase Inhibitors Prolong Cardiac Repolarization Through Transcriptional Mechanisms,” Toxicological Sciences 153 (2016): 39–54, https://doi.org/10.1093/toxsci/kfw104.

[202] P. T. Sager, B. Balser, J. Wolfson, et al., “Electrocardiographic Effects of Class 1 Selective Histone Deacetylase Inhibitor Romidepsin,” Cancer Medicine 4 (2015): 1178–1185, https://doi.org/10.1002/cam4.467.

[203] D. Zhang, C.-T. Wu, X. Qi, et al., “Activation of Histone Deacetylase-6 Induces Contractile Dysfunction Through Derailment of α-Tubulin Proteostasis in Experimental and Human Atrial Fibrillation,” Circulation 129 (2014): 346–358, https://doi.org/10.1161/CIRCULATIONAHA.113.005300.

[204] F. Liu, M. D. Levin, N. B. Petrenko, et al., “Histone-Deacetylase Inhibition Reverses Atrial Arrhythmia Inducibility and Fibrosis in Cardiac Hypertrophy Independent of Angiotensin,” Journal of Molecular and Cellular Cardiology 45 (2008): 715–723, https://doi.org/10.1016/j.yjmcc.2008.08.015.

[205] H.-Y. Duan, K.-Y. Zhou, T. Wang, et al., “Disruption of Planar Cell Polarity Pathway Attributable to Valproic Acid-Induced Congenital Heart Disease Through Hdac3 Participation in Mice,” Chinese Medical Journal 131 (2018): 2080–2088, https://doi.org/10.4103/0366-6999.239311.

[206] Y. Asare, G. Yan, and C. Schlegl, “A Cis-Regulatory Element Controls Expression of Histone Deacetylase 9 to Fine-Tune Inflammasome-Dependent Chronic Inflammation in Atherosclerosis,” Immunity 58 (2025): 555–567, https://doi.org/10.1016/j.immuni.2025.01.003.

[207] X. Peng, Z. Hu, L. Zeng, et al., “Overview of Epigenetic Degraders Based on PROTAC, Molecular Glue, and Hydrophobic Tagging Technologies,” Acta Pharmaceutica Sinica B 14 (2024): 533–578, https://doi.org/10.1016/j.apsb.2023.09.003.

[208] K. Yang, Y. Zhao, X. Nie, et al., “A Cell-Based Target Engagement Assay for the Identification of Cereblon E3 Ubiquitin Ligase Ligands and Their Application in HDAC6 Degraders,” Cell Chemical Biology 27 (2020): 866–876, https://doi.org/10.1016/j.chembiol.2020.04.008.

RIGHTS & PERMISSIONS

2025 The Author(s). Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.